SynthesisFrontiers in pharmacology2025
The impact of traditional Chinese medicine on gastrointestinal dysfunction in sepsis patients: a systematic review and network meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shenfu injection in sepsis-induced acute gastrointestinal injury: a narrative review of mechanisms and current evidence.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate, via a network meta-analysis, the efficacy and comparative differences of 16 traditional Chinese medicines-including Dachaihu Tang, Tiaoqi Tongfu Tang, Yiqi formulations, Dahuang Fuzi Tang, and Xuebijing-in treating gastrointestinal dysfunction in patients with sepsis. Effect sizes were quantified across outcome measures such as gastrointestinal dysfunction scores, traditional Chinese medicine syndrome scores, APACHE II scores, AGI grades, mean levels of D-lactate, diamine oxidase (DAO), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and intra-abdominal pressure (IAP), with the aim of providing evidence-based recommendations for precise clinical medication. Methods: Randomized controlled trials assessing the efficacy of various traditional Chinese medicines in patients with sepsis-induced gastrointestinal dysfunction were retrieved by systematically searching PubMed, Embase, Cochrane Library, Web of Science, and CNKI. Results: Traditional Chinese medicines were overall more effective than conventional treatments in improving gastrointestinal function, suppressing inflammatory responses, and repairing the intestinal mucosal barrier in patients with sepsis. Among the evaluated formulas, Dachaihu Tang showed the most significant improvement in gastrointestinal dysfunction scores [MD = -2.03, 95% CI: -3.86 to -0.20], while Yiqi formulations exhibited the most favorable effect on traditional Chinese medicine syndrome scores [MD = -5.70, 95% CI: -9.84 to -1.56]. Dahuang Fuzi Tang was most effective in improving AGI grade [MD = 0.27, 95% CI: 0.19 to 0.40], and Tiaoqi Tongfu Tang had the strongest effect on reducing IAP [MD = -4.93, 95% CI: -9.09 to -0.77]. In terms of inflammatory markers, Tiaoqi Tongfu Tang significantly reduced APACHE II scores [MD = -6.90, 95% CI: -9.66 to -4.13] and TNF-α levels [MD = -7.65, 95% CI: -10.27 to -5.04], while Houpo Heji had the most potent regulatory effect on IL-6 [MD = -4.24, 95% CI: -5.34 to -3.14]. Regarding intestinal mucosal barrier repair, Xuebijing was most effective in reducing D-lactate levels [MD = -3.51, 95% CI: -6.73 to -0.29], and had the greatest effect on improving DAO levels [MD = -4.57, 95% CI: -7.86 to -1.28]. Conclusion: This study provides an evidence-based reference for clinical decision-making. Different traditional Chinese medicines demonstrated distinct advantages in the treatment of gastrointestinal dysfunction associated with sepsis. It is recommended that clinical interventions be selected based on core pathological features: Dachaihu Tang for gastrointestinal motility disorders, Tiaoqi Tongfu Tang and Houpo Heji for prominent systemic inflammatory responses, and Xuebijing for severe mucosal barrier damage. All of these treatments showed significant superiority over conventional therapies. These findings require further validation through longer-duration, larger-sample, and higher-quality randomized controlled trials. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251062621, identifier CRD420251062621.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.